Spanish Economy Minister Luis de Guindos and EMBL Director-General Iain Mattaj have inked an agreement to host a world-class tissue imaging facility in Barcelona. The EMBLs 6th site in Europe will start work in September.
After having received market authorisation in Europe and the US for alectinib as second-line treatment for ALK-positive NSCLC, Roche presents data that qualifies the oral drug as first-line therapy.
French cancer specialist Nanobiotix has closed a €25.1m placement of shares being issued to qualified and institutional investors in the US and Europe. The company will use to funds go push commercialisation of its lead candidate NBTXR3.
As cancer immune therapy specialist Adaptimmunes R&D pipeline has expanded from 9 to 11 candidates and R&D cost rose from US$40.5m to US$63.8m, the company needed more funds.
Menarini-Silicon Biosystems Inc., a wholly owned subsidiary of Bologna-based Menarini Group, has completed the take-over of the Cellsearch Circulating Tumour Cell System from Janssen Diagnostics.
Japanese pharma major Astellas has announced it will take over private Belgian drug developer Ogeda S.A. for €800m.
Genmab A/S has announced that its CD38-targeting Phase II candidate daratumab did not reach the expected ORR in non-Hodgkins lymphoma patients. Co-developer Janssen has decided to terminate development in three NHL subtypes.
The evaluation of the European bioeconomy strategy will take longer than initially planned. According to information given at the Biostep Forum in Brussels, results won’t be available before next year and it is still unclear if there will be an update of the strategy adopted in 2012. Several upcoming expert and stakeholder meetings in 2017 will pave the way for a decision in early 2018.
Polish drug developer Selvita has out-licenced its first lead compound to Berlin-Chemie Menarini, a company of the Menarini Group. Ongoing clinical trails with SEL 24 will be conducted the company listed on Warsaw Stock Exchange and taken over later this year by Menarini.
The EUs opt-out clause for GM cultivation has missed its goal to accelerate EU market approval of safety-assessed genetically modified crops whilst giving member states the option to opt out from cultivation for political reasons.